Peripheral Blood Monocyte Abundance Predicts Outcomes in Breast Cancer Patients

Biomarkers of response are needed in breast cancer to stratify patients to appropriate therapies and avoid unnecessary toxicity. Peripheral blood gene expression and cell type abundance were used to identify biomarkers of response and recurrence in neoadjuvant chemotherapy treated breast cancer patients. Higher peripheral blood monocyte abundance after neoadjuvant chemotherapy was associated with improved prognosis in multiple independent cohorts of breast cancer patients. We used RNA sequencing on whole blood of breast cancer patients, prior to surgery, and looked for differences in gene expression by surgical outcome